We read with interest the article by Deshpande et al. 1 on bitter taste receptors (TAS2Rs) in the lungs and the expression of TAS2Rs on human airway smooth muscle (ASM). The authors describe experiments in which TAS2R agonists, such as chloroquine, evoked relaxation of mouse tracheal rings that was threefold greater in magnitude than that elicited by b-adrenergic receptor agonists 1 (the current gold-standard bronchodilator therapy for asthma and chronic obstructive pulmonary disease 2 ). We sought to investigate the uncharacteristically weak bronchodilator activity of isoproterenol in human tissue.
Deshpande et al. reply:
Belvisi et al. 1 show in human bronchi that the bitter taste receptor (TAS2R) agonist chloroquine evokes marked relaxation; this is in agreement with our findings in mouse airways 2 . They note, however, an equivalent efficacy (degree of maximal relaxation) with the b-agonist isoproterenol in human bronchi 1 . In our paper, we carried out the vast majority of intact airway physiology experiments in mice, in which we found that bitter tastants had a greater efficacy compared with isoproterenol 2 . We never stated that TAS2R agonists were more potent than b-agonists, and we note that the differences in the potency (the EC 50 ) of isoproterenol and chloroquine are comparable in our study 2 and that of Belvisi et al. 1 . In our paper, we specifically noted that the threefold greater efficacy of TAS2R agonists compared to the b-agonist isoproterenol referred to mouse airways 2 . With the limited number of human airways that we studied, we were not in a position to provide quantitative efficacy data in human airways. We have now examined additional human bronchial rings after contraction with methacholine ( Fig.  1a-c) , and we can adequately compare the efficacy of bitter tastants and isoproterenol. We find 77 ± 4.3% relaxation by isoproterenol (n = 15 experiments), whereas chloroquine and quinine achieved essentially 100% relaxation (106 ± 4.7 and 99 ± 2.9%, respectively (Fig. 1d) ). Accordingly, we still note a greater efficacy of bitter tastants compared with isoproterenol, but we recognize that it is certainly less than the threefold difference we observed in mice 2 ; we attribute this difference to a species-specific effect. Thus, we agree that in the ex vivo human airway ring model, the efficacy of these TAS2R agonists is similar to that of isoproterenol. We would like to point out, however, that the full b-agonist, isoproterenol, is not used clinically. The most commonly used inhaled b-agonist is albuterol, a partial agonist, which evokes ~60% relaxation in ex vivo studies comparing human airways that have been precontracted with muscarinic agonists and those precontracted with isoproterenol 3, 4 . Thus, from a clinical standpoint, it remains to be seen whether inhaled bitter tastants are more efficacious than this benchmark inhaled b-agonist.
Bronchodilator activity of bitter tastants in human tissue
We also note differences between our methods and those of Belvisi et al. 1 that might explain the modest decreased efficacy of isoproterenol that we find in human airways compared with quinine or chloroquine. Specifically, Belvisi et al. 1 included indomethacin in the myograph bath, contracted the bronchi with different agents, set a greater resting tension, and, in two experiments, they apparently combined data from both open strips of the main bronchi and closed rings from lower-order bronchi 1 . The authors also normalized their data (Fig. 1a,b in ref. 1 ) to the papaverine response, which further complicates interpretation because papaverine is recognized 5 as an agonist for the two highestexpressing TAS2Rs in airway smooth muscle (TAS2R10 and TAS2R14, ref.
2). Finally, we caution about interpretations of the data from Belvisi et al. 2 , which was derived from two experiments (with a representative experiment shown), as there can be variability in contractile and relaxation responses in human airway rings from intrinsic interindividual factors, chronic drug effects, and disease states.
In contrast to our paper 2 , our additional human airway data ( Fig. 1a-d) , as well as the correspondence from Belvisi et al. 1 , Morice et al. 6 found little relaxation of human bronchi to chloroquine or quinine and they found that the effect was not reversible. They also find a minimal response to saccharin 6 . With respect to saccharin, it should be noted that there is no orthologous TAS2R for saccharin in mice and saccharin does not activate bitter taste receptors in mice 7 , so we do not use this bitter tastant for physiologic studies in mice.
The kinetic data with chloroquine and quinine in human airways reported by Morice et al. 6 is in contrast to what we have found 2 . In fact, these investigators suggest these agents promote irreversible relaxation or cell injury. However, we have shown that blockade of intracellular calcium reuptake or antagonism of the large-conductance Ca 2+ activated K + channel, inhibits mouse airway relaxation to chloroquine; we have further shown that, in isolated human airway smooth muscle cells, the relaxation to bitter tastants is blocked by a PLC inhibitor 2 . The results of these interventions, which are pathway specific, would be unlikely if TAS2R agonists cause nonspecific effects or cell injury. The assertions of Morice et al. 6 are based on their finding of a slow onset of action and an inability to reverse the relaxation effect by washing human airways obtained from surgical specimens and then recontracting them with methacholine. Because the primary set of observations from our paper were obtained from inbred mice (FVB/N mice; see Supplementary Methods), we first turned to our mouse ex vivo method (in which there are no confounding variables, such as genetic differences, chronic drug treatment, or disease) to specifically address the rate and reversibility issues. In new studies using a single concentration of chloroquine (3 mM) or quinine (1 mM), the time to maximal relaxation was found to be 4.9 ± 0.24 min and 4.4 ± 0.38 min for the two drugs, respectively (n = 4, Fig. 1e ). After contraction with acetylcholine and relaxation by chloroquine or quinine, we used four exchanges of Krebs buffer in the bath, and then rechallenged with the same dose of acetylcholine. The mean time from the last wash to 90% of the maximal contraction by the subsequent acetylcholine dose was 7.2 ± 0.85 min for chloroquine and 7.8 ± 0.48 min for quinine (n = 4) (Fig. 1e) . The maximal extent of that subsequent contraction to acetylcholine compared with the first challenge was 95 ± 1.5%, and 96 ± 2.3%, respectively (P > 0.05; Fig.  1e ). Having derived these kinetic values in mice, which are compatible with what we had previously observed 2 , we then repeated these experiments in human airway rings, using 0.1 mM methacholine as the contractile agent (Fig. 1f) . The time to maximal relaxation was 8.6 ± 0.05 and 5.3 ± 0.14 min for chloroquine and quinine, respectively (n = 4), which is comparable to what we observed in mouse airways (Fig. 1e) . These values differ from those found by Morice et al. 6 , who give mean times of 34 and 23 min for the two bitter tastants. Furthermore, as in to these agonists, as well as functional recovery of contraction and a repeat relaxation, in both mouse and human airways. Together with our original studies 2 using inhibitors of the TAS2R pathway, we demonstrate airway relaxation via a receptor-mediated mechanism. These results continue to show that this previously unknown pathway may provide a new mechanism to relax smooth muscle in the treatment of obstructive airway disease. Ultimately, human trials will be required to ascertain the clinical effectiveness of TAS2R agonists in the context of diseases such as asthma and chronic obstructive pulmonary disease.
Note: Supplementary information is available on the Nature Medicine website.
the mouse airways, in human airways we observed ~90% reversal of the relaxant effect after washout and re-stimulation with methacholine (Fig. 1f) . Again, these results differ markedly from those reported by Morice et al. 6 , who did not observe any return of the contractile effect to methacholine once rings were exposed to chloroquine or quinine. Thus we demonstrate rapid on-rates, with virtually complete reversibility, in these human airways. Taken together, both mouse and human models indicate a rapid response to TAS2R agonists in a manner consistent with a typical agonist-GPCR interaction in airways, marked efficacy, and complete reversibility. Indeed, once they have been recontracted, airways can be relaxed again in a dose-dependent manner by another TAS2R agonist (Fig. 1e,f) or isoproterenol 2 . There are differences between our technique and that of Morice et al. 6 that might explain the slow onset of action and apparent irreversibility that they report for chloroquine and quinine. For our original studies 2 and those reported here, we set the resting (passive) tension at ~5-10 mN (equivalent to ~0.50 to 1.0 g), although they used tensions of 2-3 g. This lower baseline stretch placed on rings in our studies might favor TAS2R-mediated relaxation and functional recovery, whereas the greater tensions used by Morice et al. may not be conducive to relaxation by this specific mechanism or may promote cell injury in the context of the higher concentrations of TAS2R agonists that are required.
We have thus now shown the relative efficacies of isoproterenol and two TAS2R agonists in relaxing human airway smooth muscle. The efficacy of the bitter tastants, in human airways studied under our conditions, is modestly greater than that of the full b-agonist, but the relevance of this difference at the physiologic or clinical level has not been defined. We show rapid on-and off-kinetics of the relaxation
